Symbols / IMNM
IMNM Chart
About
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.51B |
| Enterprise Value | 1.76B | Income | -222.74M | Sales | 9.68M |
| Book/sh | 2.88 | Cash/sh | 2.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 168 | IPO | — |
| P/E | — | Forward P/E | -9.16 | PEG | — |
| P/S | 259.28 | P/B | 7.90 | P/C | — |
| EV/EBITDA | -8.60 | EV/Sales | 181.84 | Quick Ratio | 8.67 |
| Current Ratio | 8.90 | Debt/Eq | 1.52 | LT Debt/Eq | — |
| EPS (ttm) | -2.96 | EPS next Y | -2.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -46.48% |
| ROE | -93.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -21.37% | Profit Margin | 0.00% | Shs Outstand | 110.34M |
| Shs Float | 76.02M | Short Float | 14.79% | Short Ratio | 7.73 |
| Short Interest | — | 52W High | 27.65 | 52W Low | 5.15 |
| Beta | 2.11 | Avg Volume | 2.08M | Volume | 66.92K |
| Target Price | $35.08 | Recom | Strong_buy | Prev Close | $22.12 |
| Price | $22.75 | Change | 2.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$35.08
Mean price target
2. Current target
$22.75
Latest analyst target
3. DCF / Fair value
$-20.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.75
Low
$26.00
High
$42.00
Mean
$35.08
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-12 | init | HC Wainwright & Co. | — → Buy | $40 |
| 2026-01-15 | reit | Wedbush | Outperform → Outperform | $31 |
| 2025-12-16 | main | Lake Street | Buy → Buy | $32 |
| 2025-12-16 | main | Evercore ISI Group | Outperform → Outperform | $40 |
| 2025-12-16 | main | Guggenheim | Buy → Buy | $35 |
| 2025-12-01 | init | Truist Securities | — → Buy | $36 |
| 2025-11-17 | main | Stephens & Co. | Overweight → Overweight | $33 |
| 2025-09-22 | init | Goldman Sachs | — → Buy | $26 |
| 2025-09-05 | init | Craig-Hallum | — → Buy | $26 |
| 2025-08-25 | reit | Guggenheim | Buy → Buy | $25 |
| 2025-08-22 | init | Evercore ISI Group | — → Outperform | $18 |
| 2025-08-07 | main | JP Morgan | Overweight → Overweight | $22 |
| 2025-04-02 | init | Lake Street | — → Buy | $23 |
| 2025-03-20 | reit | Wedbush | Outperform → Outperform | $33 |
| 2025-03-20 | reit | Stephens & Co. | Overweight → Overweight | $30 |
| 2025-03-20 | main | Guggenheim | Buy → Buy | $25 |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $20 |
| 2024-11-14 | main | Piper Sandler | Overweight → Overweight | $21 |
| 2024-11-08 | init | Stephens & Co. | — → Overweight | $30 |
| 2024-10-25 | reit | Wedbush | Outperform → Outperform | $33 |
- Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance Wed, 25 Feb 2026 03
- Biotech Immunome to face investors at two March conferences - Stock Titan Mon, 23 Feb 2026 13
- Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - simplywall.st Mon, 23 Feb 2026 19
- First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq Mon, 23 Feb 2026 15
- New Analyst Forecast: $IMNM Given $40 Price Target - Quiver Quantitative hu, 12 Feb 2026 12
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire hu, 05 Feb 2026 08
- Why Is IMNM Stock Rising Today? - Stocktwits Mon, 15 Dec 2025 08
- Immunome stock falls after pricing $400 million share offering - Investing.com Wed, 17 Dec 2025 08
- Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance Fri, 16 Jan 2026 08
- $IMNM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Mon, 03 Nov 2025 08
- Immunome (Nasdaq: IMNM) posts 84% risk cut in Phase 3 desmoid tumor trial - Stock Titan Mon, 15 Dec 2025 08
- Immunome Announces Pricing of Public Offering of Common Stock - Business Wire ue, 16 Dec 2025 08
- Guggenheim Maintains Immunome (IMNM) Buy Recommendation - Nasdaq ue, 16 Dec 2025 08
- Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Yahoo Finance hu, 15 Jan 2026 08
- Immunome (Nasdaq: IMNM) to share Phase 3 RINGSIDE topline data Dec. 15 - Stock Titan Sun, 14 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4729 | 100018 | — | Purchase at price 21.15 per share. | SIEGALL CLAY B | Chief Executive Officer | — | 2025-12-30 00:00:00 | D |
| 1 | 383200 | 8330080 | — | Sale at price 21.72 - 22.34 per share. | BARCHAS ISAAC | Director | — | 2025-12-22 00:00:00 | I |
| 2 | 7278 | 149053 | — | Purchase at price 20.48 per share. | SIEGALL CLAY B | Chief Executive Officer | — | 2025-12-19 00:00:00 | D |
| 3 | 200000 | — | — | Stock Gift at price 0.00 per share. | SIEGALL CLAY B | Chief Executive Officer | — | 2025-12-19 00:00:00 | D |
| 4 | 3000 | — | — | Stock Gift at price 0.00 per share. | HIGGINS JACK | Officer | — | 2025-12-19 00:00:00 | D |
| 5 | 10000 | 204900 | — | Purchase at price 20.49 per share. | TSAI PHILIP S. L. | Chief Technology Officer | — | 2025-12-19 00:00:00 | D |
| 6 | 46511 | 999986 | — | Purchase at price 21.50 per share. | SIEGALL CLAY B | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 7 | 22000 | 29700 | — | Conversion of Exercise of derivative security at price 1.35 per share. | HIGGINS JACK | Officer | — | 2025-09-10 00:00:00 | D |
| 8 | 5000 | 46900 | — | Purchase at price 9.38 per share. | BIENAIME JEAN-JACQUES | Director | — | 2025-06-03 00:00:00 | D |
| 9 | 5200 | 7020 | — | Conversion of Exercise of derivative security at price 1.35 per share. | HIGGINS JACK | Officer | — | 2025-03-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 990.00K | 52.80M | -36.27M | -24.45M |
| TotalUnusualItems | -152.34M | -80.80M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -152.34M | -80.80M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -292.96M | -106.81M | -36.90M | -24.71M |
| ReconciledDepreciation | 2.10M | 728.00K | 631.00K | 755.00K |
| EBITDA | -151.35M | -28.00M | -36.27M | -24.45M |
| EBIT | -153.46M | -28.73M | -36.90M | -25.20M |
| NetInterestIncome | 12.84M | 2.72M | 5.00K | -10.00K |
| InterestExpense | 10.00K | |||
| InterestIncome | 12.84M | 2.72M | 5.00K | |
| NormalizedIncome | -140.62M | -26.00M | -36.90M | -24.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -292.96M | -106.81M | -36.90M | -24.71M |
| TotalExpenses | 162.50M | 42.75M | 36.90M | 25.20M |
| TotalOperatingIncomeAsReported | -305.80M | -109.53M | -36.90M | -25.20M |
| DilutedAverageShares | 58.64M | 19.84M | 12.13M | 11.54M |
| BasicAverageShares | 58.64M | 19.84M | 12.13M | 11.54M |
| DilutedEPS | -5.00 | -5.38 | -3.09 | -2.14 |
| BasicEPS | -5.00 | -5.38 | -3.09 | -2.14 |
| DilutedNIAvailtoComStockholders | -292.96M | -106.81M | -37.52M | -24.71M |
| NetIncomeCommonStockholders | -292.96M | -106.81M | -37.52M | -24.71M |
| OtherunderPreferredStockDividend | 0.00 | 622.00K | 0.00 | |
| NetIncome | -292.96M | -106.81M | -36.90M | -24.71M |
| NetIncomeIncludingNoncontrollingInterests | -292.96M | -106.81M | -36.90M | -24.71M |
| NetIncomeContinuousOperations | -292.96M | -106.81M | -36.90M | -24.71M |
| PretaxIncome | -292.96M | -106.81M | -36.90M | -24.71M |
| OtherIncomeExpense | -152.34M | -80.80M | 503.00K | |
| OtherNonOperatingIncomeExpenses | 503.00K | |||
| SpecialIncomeCharges | -152.34M | -80.80M | 0.00 | |
| OtherSpecialCharges | 152.34M | 80.80M | ||
| RestructuringAndMergernAcquisition | 152.34M | 80.80M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 12.84M | 2.72M | 5.00K | -10.00K |
| TotalOtherFinanceCost | -5.00K | 10.00K | ||
| InterestExpenseNonOperating | 10.00K | |||
| InterestIncomeNonOperating | 12.84M | 2.72M | 5.00K | |
| OperatingIncome | -153.46M | -28.73M | -36.90M | -25.20M |
| OperatingExpense | 162.50M | 42.75M | 36.90M | 25.20M |
| ResearchAndDevelopment | 129.54M | 23.09M | 23.27M | 14.11M |
| SellingGeneralAndAdministration | 32.95M | 19.66M | 13.63M | 11.09M |
| GeneralAndAdministrativeExpense | 32.95M | 19.66M | 13.63M | 11.09M |
| OtherGandA | 32.95M | 19.66M | 13.63M | 11.09M |
| TotalRevenue | 9.04M | 14.02M | 0.00 | 0.00 |
| OperatingRevenue | 9.04M | 14.02M | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 64.46M | 43.25M | 12.13M | 12.11M |
| ShareIssued | 64.46M | 43.25M | 12.13M | 12.11M |
| TotalDebt | 4.83M | 1.65M | 291.00K | 317.00K |
| TangibleBookValue | 181.16M | 119.88M | 16.65M | 48.19M |
| InvestedCapital | 181.16M | 119.88M | 16.65M | 48.19M |
| WorkingCapital | 167.03M | 122.87M | 15.32M | 46.91M |
| NetTangibleAssets | 181.16M | 119.88M | 16.65M | 48.19M |
| CapitalLeaseObligations | 4.83M | 1.65M | 291.00K | 317.00K |
| CommonStockEquity | 181.16M | 119.88M | 16.65M | 48.19M |
| TotalCapitalization | 181.16M | 119.88M | 16.65M | 48.19M |
| TotalEquityGrossMinorityInterest | 181.16M | 119.88M | 16.65M | 48.19M |
| StockholdersEquity | 181.16M | 119.88M | 16.65M | 48.19M |
| GainsLossesNotAffectingRetainedEarnings | 57.00K | 22.00K | 0.00 | |
| OtherEquityAdjustments | 57.00K | 22.00K | ||
| RetainedEarnings | -515.77M | -222.81M | -116.00M | -79.11M |
| AdditionalPaidInCapital | 696.87M | 342.66M | 132.65M | 127.29M |
| CapitalStock | 6.00K | 4.00K | 1.00K | 1.00K |
| CommonStock | 6.00K | 4.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 59.08M | 28.66M | 7.39M | 9.74M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.77M | 6.83M | 62.00K | 12.00K |
| OtherNonCurrentLiabilities | 62.00K | 12.00K | ||
| NonCurrentDeferredLiabilities | 0.00 | 5.49M | 0.00 | 12.00K |
| NonCurrentDeferredRevenue | 0.00 | 5.49M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 4.77M | 1.34M | 62.00K | |
| LongTermCapitalLeaseObligation | 4.77M | 1.34M | 62.00K | |
| CurrentLiabilities | 54.31M | 21.83M | 7.33M | 9.73M |
| OtherCurrentLiabilities | 2.13M | 732.00K | 86.00K | 317.00K |
| CurrentDeferredLiabilities | 6.94M | 10.49M | 0.00 | 2.02M |
| CurrentDeferredRevenue | 6.94M | 10.49M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 63.00K | 310.00K | 229.00K | 317.00K |
| CurrentCapitalLeaseObligation | 63.00K | 310.00K | 229.00K | 317.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.86M | 4.17M | 1.87M | 1.25M |
| PayablesAndAccruedExpenses | 39.31M | 6.12M | 5.14M | 6.14M |
| CurrentAccruedExpenses | 25.12M | 2.81M | 2.74M | 3.07M |
| Payables | 14.19M | 3.31M | 2.40M | 3.08M |
| AccountsPayable | 14.19M | 3.31M | 2.40M | 3.08M |
| TotalAssets | 240.24M | 148.54M | 24.05M | 57.92M |
| TotalNonCurrentAssets | 18.90M | 3.84M | 1.40M | 1.29M |
| OtherNonCurrentAssets | 4.51M | 200.00K | 100.00K | 100.00K |
| NonCurrentDeferredAssets | 0.00 | 332.00K | 332.00K | |
| NetPPE | 14.39M | 3.64M | 965.00K | 855.00K |
| AccumulatedDepreciation | -4.75M | -3.91M | -3.45M | -3.03M |
| GrossPPE | 19.14M | 7.54M | 4.42M | 3.88M |
| Leases | 1.64M | 233.00K | 194.00K | 193.00K |
| ConstructionInProgress | 3.30M | 0.00 | ||
| OtherProperties | 9.50M | 5.39M | 3.68M | 3.51M |
| MachineryFurnitureEquipment | 428.00K | 362.00K | 257.00K | 178.00K |
| BuildingsAndImprovements | 4.28M | 1.56M | 284.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 221.34M | 144.70M | 22.65M | 56.64M |
| OtherCurrentAssets | 4.04M | 6.56M | 876.00K | 492.00K |
| PrepaidAssets | 2.00M | 1.48M | 3.10M | |
| Receivables | 289.00K | 847.00K | 4.31M | |
| OtherReceivables | 4.31M | |||
| TaxesReceivable | 0.00 | 847.00K | ||
| AccruedInterestReceivable | 289.00K | 0.00 | ||
| AccountsReceivable | 847.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 217.30M | 138.14M | 20.32M | 49.23M |
| OtherShortTermInvestments | 73.95M | 39.46M | 0.00 | |
| CashAndCashEquivalents | 143.35M | 98.68M | 20.32M | 49.23M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -164.30M | -8.40M | -28.94M | -18.30M |
| RepaymentOfDebt | 0.00 | -113.00K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 250.00M | 125.03M | 0.00 | 27.23M |
| CapitalExpenditure | -53.51M | -831.00K | -248.00K | -79.00K |
| InterestPaidSupplementalData | 0.00 | 14.00K | ||
| EndCashPosition | 143.45M | 98.78M | 20.42M | 49.33M |
| BeginningCashPosition | 98.78M | 20.42M | 49.33M | 39.87M |
| ChangesInCash | 44.67M | 78.36M | -28.91M | 9.46M |
| FinancingCashFlow | 240.53M | 116.41M | 32.00K | 27.77M |
| CashFlowFromContinuingFinancingActivities | 240.53M | 116.41M | 32.00K | 27.77M |
| NetOtherFinancingCharges | -15.23M | -9.00M | -781.00K | |
| ProceedsFromStockOptionExercised | 5.75M | 371.00K | 32.00K | 1.44M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 250.00M | 125.03M | 0.00 | 27.23M |
| CommonStockIssuance | 250.00M | 125.03M | 0.00 | 27.23M |
| NetIssuancePaymentsOfDebt | 0.00 | -113.00K | ||
| NetLongTermDebtIssuance | 0.00 | -113.00K | ||
| LongTermDebtPayments | 0.00 | -113.00K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -85.06M | -30.48M | -248.00K | -79.00K |
| CashFlowFromContinuingInvestingActivities | -85.06M | -30.48M | -248.00K | -79.00K |
| NetInvestmentPurchaseAndSale | -31.55M | -38.93M | 0.00 | |
| SaleOfInvestment | 155.00M | 0.00 | ||
| PurchaseOfInvestment | -186.56M | -38.93M | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | 9.28M | 0.00 | |
| SaleOfBusiness | 0.00 | 9.28M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -46.34M | 0.00 | ||
| PurchaseOfIntangibles | -46.34M | 0.00 | ||
| NetPPEPurchaseAndSale | -7.17M | -831.00K | -248.00K | -79.00K |
| PurchaseOfPPE | -7.17M | -831.00K | -248.00K | -79.00K |
| OperatingCashFlow | -110.79M | -7.57M | -28.69M | -18.23M |
| CashFlowFromContinuingOperatingActivities | -110.79M | -7.57M | -28.69M | -18.23M |
| ChangeInWorkingCapital | 14.87M | 12.00M | 2.24M | 2.78M |
| ChangeInOtherWorkingCapital | -9.04M | 15.98M | ||
| ChangeInOtherCurrentLiabilities | -67.00K | 153.00K | -229.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 23.08M | 6.00K | -2.60M | 7.06M |
| ChangeInAccruedExpense | 13.55M | 614.00K | -1.92M | 5.28M |
| ChangeInPayable | 9.53M | -608.00K | -677.00K | 1.78M |
| ChangeInAccountPayable | 9.53M | -608.00K | -677.00K | 1.78M |
| ChangeInPrepaidAssets | 906.00K | -4.14M | 5.07M | -4.28M |
| OtherNonCashItems | 152.34M | 80.80M | 4.00K | |
| StockBasedCompensation | 15.75M | 6.22M | 5.33M | 3.45M |
| AmortizationOfSecurities | -2.90M | -512.00K | 0.00 | |
| DepreciationAmortizationDepletion | 2.10M | 728.00K | 631.00K | 755.00K |
| DepreciationAndAmortization | 2.10M | 728.00K | 631.00K | 755.00K |
| Depreciation | 2.10M | 728.00K | 631.00K | 755.00K |
| OperatingGainsLosses | -500.00K | |||
| NetIncomeFromContinuingOperations | -292.96M | -106.81M | -36.90M | -24.71M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IMNM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|